None listed
Conditions
Interventions
Drug : Subjects who have provided written informed consent will be randomly assigned in a 1:1 ratio to either the propranolol group or the non-propranolol group.
Randomization will be stratified by di
Sponsors
The Catholic University of Korea, Seoul St. Mary's Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Female patients aged 20 to 70 years. 2) Patients diagnosed with hypertension or angina who require medication. 3) Patients diagnosed with unilateral, resectable primary breast cancer (ICD-10: C50), Stage I-III. 4) ECOG performance status of 0-1. 5) Patients scheduled to receive standard postoperative treatment (including adjuvant radiotherapy 6) Patients who voluntarily decide to participate and sign the written informed consent form
Exclusion criteria
Exclusion criteria: 1) Patients with distant metastases. 2) Patients with active infectious diseases, autoimmune diseases (including specific rheumatic diseases), coagulation disorders, or cardiovascular diseases other than hypertension or angina pectoris. 3) Patients with clinically significant hepatic, hematologic, or renal dysfunction, defined as any of the following: ? ANC 2.5 x upper limit of normal (ULN) ? Alkaline phosphatase > 2.5 x ULN ? Total bilirubin > 1 x ULN ? Serum creatinine >1.5 x ULN or estimated creatinine clearance < 60 mL/min (as calculated using the method standard for the institution) 4) Patients with moderate to severe asthma or chronic obstructive pulmonary disease (COPD). 5) Patients who are pregnant or breastfeeding at the time of enrollment. 6) Patients with a history of malignancy within the past 5 years. 7) Patients for whom data collection is considered difficult at the discretion of the investigator. 8) Patients who are unable to understand or complete study questionnaires. 9) Patients who have received ß-blockers within 30 days prior to screening. 10) Patients with systolic blood pressure < 100 mmHg or heart rate < 55 beats per minute.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Myocardial Injury after Noncardiac Surgery (MINS): 1) 0.02–0.065 ng/mL with an absolute change of more than 0.005ng/mL or 2) any elevation =0.065 ng/mL or any absolute change more than 0.014 ng/mL | — |
Secondary
| Measure | Time frame |
|---|---|
| Perioperative Hemodynamic Stability: Comparison of the fluctuation range of vital signs, including blood pressure and heart rate;Postoperative Cardiovascular and Respiratory Complications and length of hospital stay;Change in Patient-Reported Anxiety (HADS-A);Changes in Inflammatory Markers and Serum Tumor Markers;Long-term Recurrence and Survival Outcomes;Molecular and Immunological Analysis | — |
Countries
Korea, Republic of
Contacts
Public ContactChang Ik Yoon
The Catholic University of Korea, Seoul St. Mary's Hospital
Outcome results
None listed